cyclosporine has been researched along with Liver Steatosis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benet, M; Castell, JV; Donato, MT; García-Mediavilla, MV; Guzmán, C; Jover, R; Martínez-Chantar, ML; Pisonero-Vaquero, S; Sánchez-Campos, S | 1 |
| Fujie, H; Koike, K; Matsuura, Y; Miyamura, T; Miyoshi, H; Moriishi, K; Moriya, K; Shintani, Y; Shinzawa, S; Suzuki, T; Tsutsumi, T; Yotsuyanagi, H | 1 |
| Dorn, C; Hellerbrand, C; Ledermann, M; Patsenker, E; Saegesser, H; Schneider, V; Stickel, F | 1 |
3 other study(ies) available for cyclosporine and Liver Steatosis
| Article | Year |
|---|---|
Repression of the nuclear receptor small heterodimer partner by steatotic drugs and in advanced nonalcoholic fatty liver disease.
Topics: Animals; CCAAT-Enhancer-Binding Protein-alpha; Cells, Cultured; Cyclosporine; Doxycycline; Fatty Liver; Humans; Male; Mice; Mitogen-Activated Protein Kinase 1; Non-alcoholic Fatty Liver Disease; Promoter Regions, Genetic; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Tetracycline; Thiazepines; Transcription, Genetic; Valproic Acid | 2015 |
Tacrolimus ameliorates metabolic disturbance and oxidative stress caused by hepatitis C virus core protein: analysis using mouse model and cultured cells.
Topics: Animals; Antioxidants; Cyclosporine; Disease Models, Animal; Dose-Response Relationship, Drug; Fatty Liver; Gene Expression Regulation; Glucose; Hep G2 Cells; Humans; Insulin Resistance; Lipid Metabolism; Liver; Mice; Mice, Transgenic; NAD; Oxidative Stress; Reactive Oxygen Species; RNA, Messenger; Tacrolimus; Viral Core Proteins | 2009 |
Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis.
Topics: Animals; Bile Ducts; Calcineurin Inhibitors; Cyclosporine; Disease Progression; Everolimus; Fatty Liver; Immunosuppressive Agents; Ligation; Liver Cirrhosis, Experimental; Male; Matrix Metalloproteinases; Non-alcoholic Fatty Liver Disease; Portal Pressure; Rats; Rats, Wistar; RNA, Messenger; Sirolimus; Tacrolimus; TOR Serine-Threonine Kinases; Triglycerides | 2011 |